αEβ7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis.

BACKGROUND AND AIMS The αEβ7 integrin is crucial for retention of T lymphocytes at mucosal surfaces through its interaction with E-cadherin. Pathogenic or protective functions of these cells during human intestinal inflammation, such as ulcerative colitis [UC], have not previously been defined, with understanding largely derived from animal model data. Defining this phenotype in human samples is important for understanding UC pathogenesis and is of translational importance for therapeutic targeting of αEβ7-E-cadherin interactions. METHODS αEβ7+ and αEβ7- colonic T cell localization, inflammatory cytokine production and expression of regulatory T cell-associated markers were evaluated in cohorts of control subjects and patients with active UC by immunohistochemistry, flow cytometry and real-time PCR of FACS-purified cell populations. RESULTS CD4+αEβ7+ T lymphocytes from both healthy controls and UC patients had lower expression of regulatory T cell-associated genes, including FOXP3, IL-10, CTLA-4 and ICOS in comparison with CD4+αEβ7- T lymphocytes. In UC, CD4+αEβ7+ lymphocytes expressed higher levels of IFNγ and TNFα in comparison with CD4+αEβ7- lymphocytes. Additionally the CD4+αEβ7+ subset was enriched for Th17 cells and the recently described Th17/Th1 subset co-expressing both IL-17A and IFNγ, both of which were found at higher frequencies in UC compared to control. CONCLUSION αEβ7 integrin expression on human colonic CD4+ T cells was associated with increased production of pro-inflammatory Th1, Th17 and Th17/Th1 cytokines, with reduced expression of regulatory T cell-associated markers. These data suggest colonic CD4+αEβ7+ T cells are pro-inflammatory and may play a role in UC pathobiology.

[1]  T. Barrett,et al.  p53 mediates TNF-induced epithelial cell apoptosis in IBD. , 2012, The American journal of pathology.

[2]  Graham M Lord,et al.  Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells , 2010, Nature Immunology.

[3]  E. Sgouroudis,et al.  ICOS-Dependent Homeostasis and Function of Foxp3+ Regulatory T Cells in Islets of Nonobese Diabetic Mice , 2012, The Journal of Immunology.

[4]  E. Butcher,et al.  Lymphocyte trafficking and regional immunity. , 1999, Advances in immunology.

[5]  L. Cosmi,et al.  Human interleukin 17–producing cells originate from a CD161+CD4+ T cell precursor , 2008, The Journal of experimental medicine.

[6]  J. Buer,et al.  Developmental Stage, Phenotype, and Migration Distinguish Naive- and Effector/Memory-like CD4+ Regulatory T Cells , 2004, The Journal of experimental medicine.

[7]  L. Cosmi,et al.  Phenotypic and functional features of human Th17 cells , 2007, The Journal of experimental medicine.

[8]  T. Nomura,et al.  Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. , 2009, Immunity.

[9]  C. Drachenberg,et al.  Critical Role for CD103+CD8+ Effectors in Promoting Tubular Injury following Allogeneic Renal Transplantation , 2005, The Journal of Immunology.

[10]  M. Pekalski,et al.  Renal allograft rejection: the contribution of chemokines to the adhesion and retention of alphaE(CD103)beta7 integrin-expressing intratubular T cells. , 2008, Molecular immunology.

[11]  C. Drachenberg,et al.  TGF-β–dependent CD103 expression by CD8+ T cells promotes selective destruction of the host intestinal epithelium during graft-versus-host disease , 2005, The Journal of experimental medicine.

[12]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[13]  P. Kilshaw Alpha E beta 7. , 1999, Molecular pathology : MP.

[14]  B. Rocha,et al.  A unique subpopulation of CD4+ regulatory T cells controls wasting disease, IL‐10 secretion and T cell homeostasis , 2003, European journal of immunology.

[15]  D. Podolsky,et al.  Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. , 1996, Gastroenterology.

[16]  J. Mansfield,et al.  A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis , 2012, Gut.

[17]  T. Huizinga,et al.  Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells , 2007, European journal of immunology.

[18]  Jay K Kolls,et al.  The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. , 2013, Annual review of pathology.

[19]  B. Müller-Myhsok,et al.  Role of the novel Th17 cytokine IL‐17F in inflammatory bowel disease (IBD): Upregulated colonic IL‐17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD , 2008, Inflammatory bowel diseases.

[20]  J. Mansfield,et al.  Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial , 2014, The Lancet.

[21]  C. Griscelli,et al.  A monoclonal antibody (HML‐1) defining a novel membrane molecule present on human intestinal lymphocytes , 1987, European journal of immunology.

[22]  T. Giese,et al.  Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. , 2005, Gastroenterology.

[23]  T. Yi,et al.  In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease. , 2007, Blood.

[24]  R. D. Hatton,et al.  Transforming growth factor-β induces development of the TH17 lineage , 2006, Nature.

[25]  A. Andoh,et al.  Increased expression of interleukin 17 in inflammatory bowel disease , 2003, Gut.

[26]  S. Targan,et al.  Natalizumab induction and maintenance therapy for Crohn's disease. , 2005, The New England journal of medicine.

[27]  S. Devine,et al.  CD103 Deficiency Prevents Graft-versus-Host Disease but Spares Graft-versus-Tumor Effects Mediated by Alloreactive CD8 T Cells , 2011, PloS one.

[28]  E. Shevach,et al.  GARP (LRRC32) is essential for the surface expression of latent TGF-β on platelets and activated FOXP3+ regulatory T cells , 2009, Proceedings of the National Academy of Sciences.

[29]  E. Major Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. , 2010, Annual review of medicine.

[30]  Stefan Schreiber,et al.  Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. , 2016, Gastroenterology.

[31]  P. Rutgeerts,et al.  Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.

[32]  K. Ley,et al.  Role of beta7 integrins in intestinal lymphocyte homing and retention. , 2009, Current molecular medicine.

[33]  Ting Wang,et al.  Color image segmentation using pixel wise support vector machine classification , 2011, Pattern Recognit..

[34]  R. D. Hatton,et al.  Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective , 2009, Nature Reviews Immunology.

[35]  F. Powrie,et al.  Essential role for CD103 in the T cell–mediated regulation of experimental colitis , 2005, The Journal of experimental medicine.

[36]  M. V. D. van den Brink,et al.  Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. , 2006, Blood.

[37]  Alf Hamann,et al.  Expression of the integrin αEβ7 identifies unique subsets of CD25+ as well as CD25− regulatory T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[38]  B. Ludviksson,et al.  Administration of mAb Against αEβ7 Prevents and Ameliorates Immunization-Induced Colitis in IL-2−/− Mice , 1999, The Journal of Immunology.

[39]  R. D. Hatton,et al.  The Th17 family: flexibility follows function , 2013, Immunological reviews.

[40]  L. Cosmi,et al.  Evidence for a cross-talk between human neutrophils and Th17 cells. , 2010, Blood.

[41]  A. Hayday,et al.  Epithelial decision makers: in search of the 'epimmunome' , 2010, Nature Immunology.

[42]  S. Bartlett,et al.  The epithelial cell-specific integrin, CD103 (alpha E integrin), defines a novel subset of alloreactive CD8+ CTL. , 1997, Journal of immunology.

[43]  H. Herfarth,et al.  Blocking MAdCAM-1 in vivo reduces leukocyte extravasation and reverses chronic inflammation in experimental colitis , 2004, International Journal of Colorectal Disease.

[44]  K. Papadakis,et al.  Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease. , 2008, Gastroenterology.

[45]  M. Sans,et al.  VCAM-1, but Not ICAM-1 or MAdCAM-1, Immunoblockade Ameliorates DSS-Induced Colitis in Mice , 2000, Laboratory Investigation.

[46]  A. Huisman,et al.  Automatic Nuclei Segmentation in H&E Stained Breast Cancer Histopathology Images , 2013, PloS one.

[47]  Sarah L. Brown,et al.  Efficient colonic mucosal wound repair requires Trem2 signaling , 2009, Proceedings of the National Academy of Sciences.

[48]  S. Targan,et al.  Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. , 2007, Gastroenterology.

[49]  Markus F. Neurath,et al.  Cytokines in inflammatory bowel disease , 2014, Nature Reviews Immunology.

[50]  G. Lichtenstein Progressive Multifocal Leukoencephalopathy After Natalizumab Therapy for Crohn's Disease , 2006 .

[51]  D. Beier,et al.  Mucosal T lymphocyte numbers are selectively reduced in integrin alpha E (CD103)-deficient mice. , 1999, Journal of immunology.

[52]  Kristin Stephens,et al.  Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.

[53]  Herman Waldmann,et al.  Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. , 2012, Immunity.

[54]  M. Neurath,et al.  Blockade of αEβ7 integrin suppresses accumulation of CD8+ and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo , 2016, Gut.